X连锁Alport综合征剪接异常检测及基因型-表型关联
该研究对2006年1月至2017年7月单中心疑似剪接异常患者行转录本分析,并纳入29个家系46例男性剪接异常XLAS患者,比较截短型(n=21)与非截短型(n=25)突变的基因型-表型关联。结果发现41个XLAS家系存在异常剪接模式,截短型与非截短型患者进展至ESRD的中位年龄分别为20岁(95%CI 14-23)和29岁(95%CI 25-40),差异显著(P=0.001)。
要点
- 男性XLAS剪接异常中截短型突变进展至ESRD中位年龄20岁,非截短型29岁。
- 转录本水平分析可区分截短型与非截短型剪接异常,指导预后判断。
- 截短型剪接突变或可探索剪接调节治疗。
核心结论
- 男性XLAS患者COL4A5基因存在不可预测的非典型剪接,截短型与非截短型剪接异常者的肾脏预后显著不同。
研究设计与样本
- 单中心2006年1月至2017年7月对疑似剪接异常患者行转录本表达分析,并纳入29个家系46例男性剪接异常XLAS患者进行基因型-表型关联分析。
主要发现
- 检测到41个XLAS家系存在异常剪接模式,并描述了14种新的非典型剪接模式。
- 截短型突变患者进展至ESRD的中位年龄为20岁(95%CI 14-23),非截短型为29岁(95%CI 25-40),P=0.001。
关键数值与推荐
- 截短型剪接异常(n=21,来自14个家系)与非截短型(n=25,来自15个家系)在转录本水平比较。
临床怎么用
- 对疑似剪接异常的XLAS患者应行转录本分析以明确突变类型并判断预后。
- 截短型剪接突变患者可考虑探索剪接调节治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: X-linked Alport syndrome (XLAS) is a progressive hereditary nephropathy caused by mutations in the COL4A5 gene. Genotype-phenotype correlation in male XLAS is relatively well established; relative to truncating mutations, nontruncating mutations exhibit milder phenotypes. However, transcript comparison between XLAS cases with splicing abnormalities that result in a premature stop codon and those with nontruncating splicing abnormalities has not been reported, mainly because transcript analysis is not routinely conducted in patients with XLAS. METHODS: We examined transcript expression for all patients with suspected splicing abnormalities who were treated at one hospital between January of 2006 and July of 2017. Additionally, we recruited 46 males from 29 families with splicing abnormalities to examine genotype-phenotype correlation in patients with truncating (n=21, from 14 families) and nontruncating (n=25, from 15 families) mutations at the transcript level. RESULTS: We detected 41 XLAS families with abnormal splicing patterns and described novel XLAS atypical splicing patterns (n=14) other than exon skipping caused by point mutations in the splice consensus sequence. The median age for developing ESRD was 20 years (95% confidence interval, 14 to 23 years) among patients with truncating mutations and 29 years (95% confidence interval, 25 to 40 years) among patients with nontruncating mutations (P=0.001). CONCLUSIONS: We report unpredictable atypical splicing in the COL4A5 gene in male patients with XLAS and reveal that renal prognosis differs significantly for patients with truncating versus nontruncating splicing abnormalities. Our results suggest that splicing modulation should be explored as a therapy for XLAS with truncating mutations.
引用
- Horinouchi T, Nozu K, Yamamura T, et al. Detection of Splicing Abnormalities and Genotype-Phenotype Correlation in X-linked Alport Syndrome. J Am Soc Nephrol. 2018. PMID: 29959198. doi:10.1681/ASN.2018030228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。